Cytosorbents CORP Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Avenir Corporation and James H. Rooney have reported a beneficial ownership of 8.33% in Cytosorbents Corp's common stock.
NASDAQ
SCHEDULE 13G: Avenue Capital Entities Disclose Significant Stake in Cytosorbents Corp Through Convertible Debt and Warrants
Avenue Venture Opportunities Funds and related entities have disclosed a combined beneficial ownership of 5.7% in Cytosorbents Corp, primarily through convertible loans and warrants.
NASDAQ
The Vanguard Group has filed an amended Schedule 13G, disclosing a 3.11% beneficial ownership stake in CytoSorbents Corp as of March 31, 2025.
NASDAQ
Skylands Capital, LLC has disclosed a passive beneficial ownership of 4.8% of CytoSorbents Corporation's common stock as of March 31, 2025.
NASDAQ
Avenir Corporation and James H. Rooney have disclosed a shared beneficial ownership of 5.66% of Cytosorbents Corp's common stock as of December 31, 2024.
NASDAQ
The Vanguard Group has reported a 7.13% passive beneficial ownership stake in CytoSorbents Corp's common stock as of December 31, 2024.
NASDAQ
SCHEDULE 13G: Key Investor Thomas Satterfield, Jr. Discloses 6.56% Stake in CytoSorbents Corporation
Thomas A. Satterfield, Jr. has disclosed a beneficial ownership of 6.56% of CytoSorbents Corporation's common stock, totaling 3,998,867 shares, as of January 13, 2025.
NASDAQ
Skylands Capital, LLC has reported a 5.1% beneficial ownership stake in CytoSorbents Corporation, holding 2,781,622 shares of common stock as of December 31, 2024.